We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $9.37B
1-Year Est. Return 36.4%
This Fund
S&P 500
This Quarter Est. Return
+19.94%
1 Year Est. Return
+36.4%
3 Year Est. Return
+114.29%
5 Year Est. Return
+137.63%
10 Year Est. Return
+514.19%
AUM
$9.37B
AUM Growth
+$1.16B
Cap. Flow
+$125M
Cap. Flow %
1.34%
Top 10 Hldgs %
19.5%
Holding
1,860
New
177
Increased
769
Reduced
722
Closed
101

Top Sells

Rank Stock Value
1
VET icon
Vermilion Energy
VET
+$20.6M
2
PL icon
Planet Labs
PL
+$17M
3
MRVL icon
Marvell Technology
MRVL
+$12.3M
4
ASTS icon
AST SpaceMobile
ASTS
+$10.5M
5
MSFT icon
Microsoft
MSFT
+$10.3M

Sector Composition

Rank Sector Weight
1 Miscellaneous 30.92%
2 Technology 22.36%
3 Industrials 9.58%
4 Financials 8.95%
5 Healthcare 6.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BTG icon
1726
B2Gold
BTG
$7.41B
$88.6K ﹤0.01%
+23,700
New +$109K
LAND
1727
Gladstone Land Corp
LAND
$424M
$85.3K ﹤0.01%
10,004
-1,817
-15% -$17.4K
MGF
1728
Aberdeen Government Markets Income Fund
MGF
$92.9M
$74.3K ﹤0.01%
25,891
+6,669
+35% +$19.2K
UAA icon
1729
Under Armour
UAA
$2.26B
$71.8K ﹤0.01%
+11,236
New +$66.6K
STLA icon
1730
Stellantis
STLA
$16.1B
$67.9K ﹤0.01%
+11,837
New +$87.6K
TV icon
1731
Televisa
TV
$1.39B
$66K ﹤0.01%
24,361
SNAP icon
1732
Snap
SNAP
$9.25B
$63.8K ﹤0.01%
14,373
+3,986
+38% +$21.8K
NRO
1733
Neuberger Real Estate Securities Income Fund Inc
NRO
$181M
$62.2K ﹤0.01%
20,533
+630
+3% +$1.88K
ZNTL icon
1734
Zentalis Pharmaceuticals
ZNTL
$378M
$61.4K ﹤0.01%
+12,656
New +$50.5K
BMBL icon
1735
Bumble
BMBL
$383M
$61.1K ﹤0.01%
19,100
+6,700
+54% +$22.9K
ABR icon
1736
Arbor Realty Trust
ABR
$979M
$59.7K ﹤0.01%
11,014
-2,881
-21% -$18.7K
HRZN icon
1737
Horizon Technology Finance
HRZN
$324M
$57.8K ﹤0.01%
+12,213
New +$52.8K
LAC
1738
Lithium Americas
LAC
$1.09B
$56K ﹤0.01%
+14,550
New +$69.3K
IGR
1739
CBRE Global Real Estate Income Fund
IGR
$681M
$55.9K ﹤0.01%
12,136
+127
+1% +$590
SPRO icon
1740
Spero Therapeutics
SPRO
$70.5M
$50.5K ﹤0.01%
+22,850
New +$59.8K
TCPC icon
1741
BlackRock TCP Capital
TCPC
$341M
$48K ﹤0.01%
14,300
-2,000
-12% -$7.76K
ALIT icon
1742
Alight
ALIT
$398M
$47.6K ﹤0.01%
4,250
+1,750
+70% +$24.8K
NFGC
1743
New Found Gold
NFGC
$696M
$45.1K ﹤0.01%
29,300
+11,800
+67% +$22.6K
DHY
1744
UBS Asset Management High Yield Credit Fund
DHY
$233M
$44.5K ﹤0.01%
25,000
ABEV icon
1745
Ambev
ABEV
$46.6B
$40.5K ﹤0.01%
+12,906
New +$40.3K
EVTL icon
1746
Vertical Aerospace
EVTL
$103M
$35.7K ﹤0.01%
20,500
-2,000
-9% -$4.8K
CLVT icon
1747
Clarivate
CLVT
$1.32B
$34.6K ﹤0.01%
16,000
-23,500
-59% -$57.5K
CGEN icon
1748
Compugen
CGEN
$245M
$33.2K ﹤0.01%
+15,500
New +$38.8K
LUCD icon
1749
Lucid Diagnostics
LUCD
$179M
$32.1K ﹤0.01%
30,000
LRMR icon
1750
Larimar Therapeutics
LRMR
$398M
$30.5K ﹤0.01%
10,000

Similar funds

Oppenheimer & Co's Q2 2026 Portfolio in Review

As of Q2 2026, Oppenheimer & Co held 1,860 positions worth $9.37B, up 14% from $8.21B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Oppenheimer & Co's Q2 2026 filing shows 177 new, 769 increased, 722 reduced and 101 closed positions. Its largest new stake was Vanguard US Momentum Factor ETF: 40,457 shares worth $10.1M. The largest sale was Vermilion Energy, an estimated $20.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 31% of assets, up from 30% a quarter earlier, followed by Technology and Industrials.

  • Oppenheimer & Co's largest Q2 2026 buy was Vanguard US Momentum Factor ETF: 40,457 shares worth $10.1M.
  • Oppenheimer & Co added most to Eaton Vance Total Return Bond ETF in Q2 2026, an estimated $8.85M increase.
  • Oppenheimer & Co's biggest Q2 2026 reduction was Vermilion Energy, cutting an estimated $20.6M.
  • Oppenheimer & Co fully exited Invesco CurrencyShares Swiss Franc Trust in Q2 2026, selling an estimated $3.47M.
  • Oppenheimer & Co's ten largest holdings make up 19% of its $9.37B portfolio in Q2 2026.
  • Oppenheimer & Co opened 177 new positions and closed 101 in Q2 2026.
  • Oppenheimer & Co's portfolio value rose 14% quarter-over-quarter to $9.37B.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.